Released on = February 14, 2007, 8:47 am

Press Release Author = La Merie Business Intelligence

Industry = Biotech

Press Release Summary = The growing market of recombinant coagulation factors posted
2006 sales of more than US$ 4.6 bln. The four market leaders compete with a
staggered series of next generation products and face competition by new entrants
into the various segments of the field

Press Release Body = BARCELONA, Spain | Feb 14, 2007 | The Business Intelligence
firm La Merie S.L. reported today that the global market of recombinant coagulation
factors VIIa, VIII and IX posted strong 2006 sales of more than US$ 4.6 bln. The
still growing market of recombinant coagulation factors has marginated human
plasma-derived products. Competition between Baxter, Bayer and Wyeth in the
recombinant F. VIII segment (sales of US$ 2.8 bln) has spurred the launch of safer,
animal and human protein free, products formulated with sucrose or trehalose. More
convenient presentation formats of existing products are a current differentiation
strategy. Development of next generation Factor VIII products is based on prolonging
the half-life of the existing proteins by drug delivery technologies. This
competitive field is pioneered by Bayer Schering Pharma ahead of Baxter and Wyeth
with a clinical phase I project and joined by Novo Nordisk as a new entrant into the
F. VIII segment. Research stage projects are based on protein engineering and
peptide technologies. These approaches aim at generating long-acting and more potent
molecules with Factor VIII activity to allow non-iv, less frequent or even oral
administration. These results and more were found in a Competitor Analysis conducted
by La Merie Business Intelligence. The report can be found at www.pipelinereview.com
, La Merie's News Center and Online Store

Novo Nordisk occupies the recombinant F. VIIa market and has advanced activities in
extending the label by new indications, such as bleeding, surgery and brain injury.
Novo Nordisk's next generation V. VIIa projets face competition by Roche &
collaborator attracted by the monopolistic US$ 1 bln market expected to further grow
by new indications. Novo Nordisk's recent decision to focus on protein therapeutics
also finds its materialization in R&D projects with F. VIII, F. IX and F. XIII. The
acquisition of Syntonix, Biogen Idec is entering the field of recombinant next
generation coagulation factors by use of Syntonix' Transfuson and Transceptor
technologies. Market leader Baxter is opening a new market with its R&D activities
of recombinant von Willebrand factor. Purified human and recombinant human versions
of thrombin are in the registration process and expected to squeeze out bovine
thrombin products.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high
quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals. For more
information visit www.lamerie.com.



About R&D Pipeline News

R&D Pipeline News is a premier information source about research and development
projects in the pipeline of the biopharmaceutical industry and is directed to all
stakeholders in R&D. The weekly publication comes in a rapid- and easy-to-screen
tabular format and provides access to the original information source via
hyperlinks. R&D Pipeline News covers all relevant treatment modalities and is
directly delivered to the desktop via e-mail.

More information about the journal, a free trial and subscriptions are available via
La Merie's Business Intelligence Center www.pipelinereview.com.

SOURCE: La Merie Business Intelligence



Web Site = http://www.pipelinereview.com/joomla/content/view/9850/1/

Contact Details = Jorge Márquez
C/Casp 33 B 4º 2ª.
08010 Barcelona
Tel + 34 93 342 91 97
Fax + 93 342 91 98
eMail: jorge.marquez@lamerie.com
http://www.lamerie.com